HopeStage
Back to all studies
CompletedNCT01614093

Oxytocin and Fullness Signals in People With Schizophrenia

About this titleRead the official source — NCT01614093
Medication studyAges 18–54United States
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 54 years. Other eligibility criteria applied.

Listed locations
CatonsvilleSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJune 2012
Recruitment status
Completed
Enrollment listed in the registry
24
Sponsor
University of Maryland, Baltimore
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
United States
Age range
From 18 Years to 54 Years
Official registry ID
NCT01614093
Official title
Show the full official title

Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Catonsville

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University of Maryland, Baltimore, a university.

Did this study involve medication?

Yes. The study involved medication, including Oxytocin and Placebo.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 54 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies